



September 15, 2023

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/
Tenofovir Disproxil Fumurate tablets”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets

- *Strides' NDA 505b2 is tentatively approved under USFDA's expedited review provision for the President's Emergency Plan for AIDS Relief (PEPFAR)*

Bangalore, India, Sep 15, 2023 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for its New Drug Application (NDA) 505b2 of Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets from the United States Food & Drug Administration (USFDA). The Product will be manufactured at the company's facility in Bengaluru.

Approval of this product under the PEPFAR program completes Strides' qualification to all major markets and donor programs including Global Fund and South Africa.

The PEPFAR tentative approval for Strides qualifies the Company to participate in the PEPFAR programs that procure this lifesaving medicine. Through country tenders and donor funded programs it is estimated that the value of procurement for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets is ~650mn USD.

The Company has 260+ cumulative NDA/ ANDA filings with USFDA, of which 230+ ANDAs have been approved. The Company has set a target to launch ~ 60 new products over the next three years in the US.

About Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets

Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets is a complete regimen for treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kgs.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

For further information, please contact:

| | |
|---|---|
| <p><u>Strides</u> Badree Komandur Executive Director – Finance & Group CFO +91 80 6784 0747</p> <p><u>Strides Pharma Science Limited</u> CIN: L24230MH1990PLC057062</p> <p>Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703</p> <p>Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076</p> | <p><u>Corporate Communication</u> Pallavi Panchmatia: +91 80 6784 0193 Email: pallavi.panchmatia@strides.com</p> <p><u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com Boni Mukherjee: +91 96186 82208 boni@fortunapr.com</p> |
|---|---|